Last reviewed · How we verify
Drug: Topical Rapamycin
At a glance
| Generic name | Drug: Topical Rapamycin |
|---|---|
| Also known as | topical rapamycin 1% |
| Sponsor | Clinica Universidad de Navarra, Universidad de Navarra |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Combination Gerotherapeutic Interventions for Healthspan Improvement (PHASE3)
- Daily Topical Rapamycin for Vitiligo (PHASE2)
- Topical Sirolimus in Cutaneous Lymphatic Malformations (PHASE2)
- Topical-RAPA Use in Inflammation Reversal and Re-setting the Epigenetic Clock (EARLY_PHASE1)
- Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease (PHASE1)
- RAPA-Keloid Study of Keloid Regression (EARLY_PHASE1)
- NPC-12G Gel 0.2% Sirolimus PK Bridging Study (PHASE1)
- Topical Rapamycin and Calcitriol for Angiofibroma of Tuberous Sclerosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: